Breaking
Stämm launches High-Throughput Bioprocessor (HTB) for decentralized biomanufacturing - March 2026 Yuyo Llamazares Vegh named Endeavor Entrepreneur 2023 Former Merck KGaA CEO Stefan Oschmann joins Stämm board Stämm closes $17M Series A led by Varana Capital with Draper Associates Stämm's desktop bioreactor makes cell therapy manufacturing modular and scalable From beer brewing in Buenos Aires to San Francisco deeptech - Yuyo Llamazares Vegh's decade-long bet Stämm launches High-Throughput Bioprocessor (HTB) for decentralized biomanufacturing - March 2026 Yuyo Llamazares Vegh named Endeavor Entrepreneur 2023 Former Merck KGaA CEO Stefan Oschmann joins Stämm board Stämm closes $17M Series A led by Varana Capital with Draper Associates Stämm's desktop bioreactor makes cell therapy manufacturing modular and scalable From beer brewing in Buenos Aires to San Francisco deeptech - Yuyo Llamazares Vegh's decade-long bet
CEO & Co-Founder

Yuyo
Llamazares
Vegh

Stämm Biotech  ·  San Francisco  ·  Argentina

He shrank a factory-floor bioreactor to desktop size. Then he shrunk the cost, the complexity, and the excuse for not making biologics at scale. Stämm is what happens when an agricultural engineer decides the pharma industry's infrastructure is simply wrong.

$17M+
Total Raised
2016
Founded
3
Continents
250+
Team Members
Yuyo Llamazares Vegh, CEO and Co-Founder of Stämm
Yuyo Llamazares Vegh  ·  Stämm Biotech

The Brew That Started It All

Somewhere in Buenos Aires, a twelve-year-old learned to brew beer from his grandfather. Not because he wanted a career in biotech - because he wanted a specific kind of beer and the liquid yeast he needed wasn't sold anywhere. So he made it himself. That kid was Yuyo Llamazares Vegh, and the habit of building what doesn't exist yet never left him.

Years later, studying Agricultural Engineering at the University of Buenos Aires - a discipline that turns out to be a straight line toward controlling biological systems at scale - Yuyo realized the beer problem was everywhere. The tools available to anyone who wanted to manufacture something biological were outdated, expensive, difficult to scale, and fragile. The will to build was there. The infrastructure wasn't.

In 2016, Yuyo and his cousin Federico D'Alvia Vegh co-founded Stämm. The name comes from the German word for "stem" or "trunk" - the root of things. The mission was blunt: redesign biomanufacturing from scratch. Not incrementally improve existing bioreactors, but rethink what a bioreactor should be if you were building it today.

Stämm's answer arrived in the form of desktop-sized, 3D-printed microfluidic bioreactors - modular units that control physical parameters with precision, eliminate gas bubbles that damage cells, and scale by adding more modules rather than by building bigger vessels. It looks nothing like what the pharmaceutical industry has been using for decades. That's the point.

The company ran through IndieBio's Cohort 7 in 2018, caught the attention of SOSV's biotech accelerators, and in 2022 closed a $17 million Series A led by Varana Capital, with Tim Draper's Draper Associates and SOSV among the backers. By 2023, Stefan Oschmann - the man who ran Merck KGaA as CEO and Chairman, who spent 22 years inside one of pharma's largest empires - joined Stämm's board. That same year, Yuyo was named an Endeavor Entrepreneur, joining a global network that includes the founders of MercadoLibre and Globant.

In March 2026, Stämm launched the High-Throughput Bioprocessor (HTB) - a bubble-free, automated platform for decentralized production of biologics and cell therapies. Not a prototype. A product.

"We detected this breach between the will to develop a biological product and the abilities of tools that were out in the market."
- Yuyo Llamazares Vegh
Origin, Buenos Aires

Yuyo and Federico D'Alvia Vegh are cousins. They co-founded Stämm together, meaning family is literally encoded into the company's DNA. Federico serves as COO; Yuyo as CEO.

Family & Founding
Name Meaning

His nickname "Yuyo" is Argentine slang for a wild plant or weed - something that grows where it isn't supposed to, unbothered by the conditions around it. Appropriate for someone building technology that the established industry said wasn't necessary.

Fun Fact

Education

Agricultural Engineering, University of Buenos Aires - with specialization in Phytopathology and Bioprocesses. The kind of degree that teaches you to understand living systems before you try to engineer them.

The Technology

What Stämm Actually Built

Bioreactors have been roughly the same for decades - large, expensive vessels that require expertise to operate and facilities to house. Stämm rethought every assumption.

🔬

Microfluidic Precision

Fine-grained control of nutrients, dissolved oxygen, and physical parameters at the cellular level. Individual cells perform better - more productivity per cell, less waste per batch.

🖨️

3D-Printed Architecture

The bioreactor itself is 3D printed - enabling rapid iteration, customization, and the production of geometries that traditional manufacturing cannot achieve.

📦

Modular Scaling

Scale up by adding modules, not by building bigger tanks. The same platform that runs a research experiment runs a production batch - without the traditional "scale-up problem."

🧬

Bubble-Free Design

Gas bubbles damage cells in suspension. Stämm's HTB eliminates them entirely - a design choice that protects cell viability and improves output quality across biologics and cell therapies.

Continuous Production

Unlike batch bioprocessing, Stämm's platform supports continuous industrial production - the first methodology of its kind for both biological products and cellular therapies.

🌐

Decentralized Manufacturing

Desktop-sized means biologics production can happen anywhere - not just in centralized pharmaceutical facilities. The same logic that moved computing from mainframes to laptops, applied to bioprocessing.

Funding & Backers

Who Bet on the Bioreactor

2016

Founded

Stämm co-founded in Buenos Aires by Yuyo Llamazares Vegh and Federico D'Alvia Vegh. Zero funding, one idea: rebuild biomanufacturing infrastructure from the ground up.

2018

IndieBio Cohort 7

Accepted into SOSV's IndieBio accelerator - the biotech world's most competitive early-stage program, based in San Francisco. First major institutional validation.

SOSV IndieBio
2022

$17M Series A

Series A led by Varana Capital, with Draper Associates, SOSV's IndieBio, Decarbonization Consortium, Grid Exponential, and others. Funds used for commercialization, biopharma partnerships, and team growth.

Varana Capital Draper Associates SOSV Decarbonization Consortium Grid Exponential
2023

Series B & Board Expansion

Stefan Oschmann - former CEO and Chairman of Merck KGaA - appointed to the board. New investors include Endeavor Global, Eridani Ventures, AIR Capital, and High House Investment.

Stefan Oschmann Endeavor Global Eridani Ventures AIR Capital
2026

HTB Product Launch

Launch of the High-Throughput Bioprocessor - a fully automated, bubble-free biomanufacturing platform for decentralized production. Stämm's commercial moment.

$17M+ Total Capital Raised
18+ Investors & Partners
10 Years in the Making

Stefan Oschmann

Former CEO & Chairman, Merck KGaA. 22-year tenure at Merck & Co. Appointed Independent Director to Stämm's board in July 2023. Brings global pharma operations expertise to Yuyo's team.

Why the Infrastructure Was Wrong

The conventional bioreactor is a product of a different era. Designed for industrial-scale pharmaceutical manufacturing, it assumes a centralized model: large facilities, highly trained operators, expensive equipment that takes years to qualify for regulatory use. That model worked when the goal was to produce a handful of blockbuster drugs at massive scale. It breaks down when the goal is something else entirely.

Cell therapies, gene therapies, and personalized biologics don't want massive centralization. They want proximity to patients, flexibility across cell types, and the ability to adapt without rebuilding an entire facility. Yuyo spotted this gap not by reading industry reports but by working in it - watching biological researchers and small manufacturers hit the same walls, over and over, because the tools simply weren't designed for their reality.

Stämm's response was to go smaller, not bigger. The miniaturization wasn't just about physical footprint - it was about rethinking what parameters matter at the cellular level. By building in microfluidic precision from the start, Stämm could control conditions that industrial-scale bioreactors smooth over with brute force. The result: individual cells that perform better because the environment they're in is actually optimized for them.

The 3D printing angle emerged from the same logic. Traditional bioreactor manufacturing requires machined metal, complex assembly, and expensive qualification. 3D printing allows geometries that don't exist otherwise, enables rapid iteration without tooling costs, and produces single-use components that eliminate cross-contamination risk between batches. It's not a gimmick - it's a manufacturing philosophy.

What Yuyo has built is closer to a platform than a product. The same modular architecture that handles CHO cell culture for monoclonal antibody production can be reconfigured for CAR-T cell expansion, stem cell work, or cultivated meat. The modularity is the business model: add more units, don't build bigger tanks. The laboratory setting and the production setting converge.

Career Timeline

2007Agricultural Engineering, University of Buenos Aires
2016Co-founded Stämm; Singularity University Global Solutions Program
2018IndieBio (SOSV) Cohort 7 - San Francisco
2022$17M Series A - Varana Capital & Draper Associates
2023Endeavor Entrepreneur; Stefan Oschmann joins Stämm board
2026High-Throughput Bioprocessor (HTB) launched
Track Record

What He's Built and Won

01

IndieBio Cohort 7 Graduate

Selected for SOSV's IndieBio accelerator in San Francisco - the most competitive biotech program globally. Where Stämm went from prototype to fundable company.

02

$17M Series A at Varana/Draper

Raised $17 million with Tim Draper's Draper Associates as co-lead - one of Silicon Valley's most storied early-stage investors, known for betting on Bitcoin and SpaceX early.

03

Endeavor Entrepreneur 2023

Joined Endeavor's global network - the same network that includes Marcos Galperin (MercadoLibre), the founders of Globant, and hundreds of high-impact entrepreneurs across Latin America.

04

Stefan Oschmann on the Board

Attracted the former CEO and Chairman of Merck KGaA as an Independent Director - a signal that the largest pharmaceutical institutions are taking Stämm's platform seriously.

05

Singularity University 2016

Selected for the Global Solutions Program - a moonshot innovation program designed for founders working on problems that can affect a billion people. Yuyo applied it to biomanufacturing.

06

HTB Product Launch, 2026

Released the High-Throughput Bioprocessor - a fully automated, bubble-free biomanufacturing platform. After a decade of development, Stämm's first commercial product is in the market.

Watch & Listen

Yuyo in His Own Words

Interviews, demo days, and conversations where Yuyo explains the problem and the platform in depth.

Draper Cygnus Tech Week

Biomanufacturing in LATAM with Yuyo Llamazares

Yuyo discusses the opportunity for biomanufacturing in Latin America and Stämm's role in building regional biotech infrastructure.

Demo Day

Stämm - Live Demo Day Q&A

Stämm's demo day presentation and live Q&A - covering the technology, market opportunity, and vision for decentralized biomanufacturing.

Cultivated Meat

Disrumpir la vaca - Yuyo Llamazares

Deep dive into how Stämm's technology applies to cultivated meat manufacturing - one of the most capital-intensive challenges in alternative proteins.

Interview Series

E4. Yuyo Llamazares de Stamm

A long-form interview exploring Yuyo's background, the founding of Stämm, and his perspective on building deep tech from Latin America to global markets.

The Details

Five Things Worth Knowing

01 / 05

His nickname "Yuyo" is Argentine slang for a weed - a plant that grows where it isn't supposed to, in conditions that would stop something more delicate. He runs a biotech company, which tracks.

02 / 05

The origin of Stämm traces to home brewing beer with his grandfather at age 12 - one of humanity's oldest bioprocesses. He needed liquid yeast, couldn't buy it, and made his own. The rest followed.

03 / 05

He co-founded a company with his cousin. Federico D'Alvia Vegh is Stämm's COO. In an industry where co-founder breakups are nearly as common as funded startups, building with family is a different kind of bet.

04 / 05

Stämm has offices on three continents: Buenos Aires (Argentina), San Francisco (USA), and Switzerland. The technology built for global deployment was built by a team that already spans the globe.

05 / 05

His path from agricultural engineering - studying how diseases spread in plants and how organisms grow - to bioprocessing hardware is a straight line. Both fields are about controlling biology at scale.

+

Stämm's name comes from the German word for "stem" or "trunk" - the foundational part of a living system. Naming a biotech company after the root of things is either deliberate or poetic. Probably both.

Share Yuyo's Story

From Buenos Aires to San Francisco - a decade building the infrastructure biology needs.

Link copied to clipboard.